Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 4/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.48 |
| ▸ | ESR1 | P03372 | 4/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7105837 | 0.99 | EBP (0.62) | EBPSIGMAR1LTA4HHRH3ESR1 | |
| SCHEMBL7109917 | 0.96 | EBP (0.56) | EBPSIGMAR1LTA4HHRH3SLC6A4 | |
| SCHEMBL7108683 | 0.94 | EBP (0.59) | EBPSIGMAR1LTA4HHRH3ESR1 | |
| SCHEMBL7110375 | 0.94 | EBP (0.56) | EBPSIGMAR1LTA4HHRH3ESR1 | |
| SCHEMBL7521111 | 0.94 | EBP (0.70) | EBPSIGMAR1LTA4HHRH3ESR1 | |
| SCHEMBL3975634 | 0.93 | EBP (0.72) | EBPSIGMAR1LTA4HHRH3ESR1 | |
| SCHEMBL7524285 | 0.92 | EBP (0.65) | EBPSIGMAR1LTA4HHRH3ESR1 | |
| SCHEMBL13897766 | 0.92 | EBP (0.65) | EBPSIGMAR1LTA4HHRH3ESR1 | |
| SCHEMBL13897747 | 0.91 | EBP (0.66) | EBPSIGMAR1LTA4HHRH3ESR1 | |
| SCHEMBL7109841 | 0.90 | EBP (0.57) | EBPSIGMAR1LTA4HHRH3ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0832880-B1 | Dihydrobenzofluorene compounds, intermediates, compositions, and methods | LILLY CO ELI (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| US-5792762-A | TREATING BONE DISORDER, OSTEOPOROSIS, CARDIOVASCULAR DISORDER; ANTICHOLESTEROL AGENTS | ELI LILLY AND COMPANY (US) | 1998-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | NDC1, SQLE, NQO1 | EBP 1842/4885SIGMAR1 1661/4885LTA4H 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.